Renewed Investor Appetite in Biotech Innovation Means Strong Attendance Expected at BioPharm America™ 2014
The seventh annual BioPharm America™ international life science partnering conference will be held September 22–24 at Boston Marriott Copley Place in the center of Boston’s historic Back Bay. The event is a big draw for pharma and investors who want to access innovative new potential therapies and cures brought by international biotech companies.
The investment climate is excellent in 2014, and venture capital attendance at BioPharm America will be stronger than ever. Investors already confirmed to attend include: Philip Astley-Sparke, Venture Partner at Forbion Capital Partners; Peter Barrett, Partner, Atlas Venture; Cedric Bisson, Venture Partner at Teralys Capital; Bruce Booth, Partner at Atlas Venture; Bernard Davitian, VP and Managing Director at Sanofi-Genzyme BioVentures, Sanofi; Todd Foley, Managing Director at MPM Capital; Brian Gallagher, Partner at SR One; Jim Geraghty, Entrepreneur-in-Residence at Third Rock Ventures; Frederick Jones, Director at Broadview Ventures, Inc.; Nilesh Kumar, Director at MS Ventures; Dan Liu, Senior Associate at Mitsui Global Investment; Ed Mathers, Partner at New Enterprise Associates; Takahiro Mukohira, President at MP Healthcare Venture Management; Liam Ratcliffe, Managing Director at New Leaf Venture Partners; Kevin Starr, Partner at Third Rock Ventures; and Robert Weisskoff, Partner at Fidelity Biosciences.
Presenting companies at BioPharm America represent some of the most innovative companies ranging from early stage projects and small entrepreneurial companies, to established biotech companies. The 2014 list includes Acetylon Pharmaceuticals, Inc.; AnaptysBio, Inc.; Apitope; Avexxin AS; Cerecor Inc.; Cerulean Pharma Inc.; Charleston Laboratories, Inc.; Dicerna; Gene Signal; Igenica Biotherapeutics; Poxel SA; RedHill Biopharma; Rexahn Pharmaceuticals; RXi Pharmaceuticals; Selvita S.A.; uniQure; and Vaccinex, Inc, Les
